Tilray, Inc. Share Price Toronto S.E.
Equities
APHA
CA03765K1049
Pharmaceuticals
Sales 2024 * | 783M 1.07B 62.32B | Sales 2025 * | 864M 1.18B 68.81B | Capitalization | 1.6B 2.19B 128B |
---|---|---|---|---|---|
Net income 2024 * | -226M -309M -18B | Net income 2025 * | -85M -116M -6.77B | EV / Sales 2024 * | 2.28 x |
Net Debt 2024 * | 178M 243M 14.17B | Net Debt 2025 * | 108M 148M 8.64B | EV / Sales 2025 * | 1.98 x |
P/E ratio 2024 * |
-6.05
x | P/E ratio 2025 * |
-14
x | Employees | 1,600 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.73% |
Latest transcript on Tilray, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 29/04/21 |
Carl Merton
DFI | Director of Finance/CFO | - | 29/04/21 |
Lloyd Brathwaite
CTO | Chief Tech/Sci/R&D Officer | - | 29/04/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 29/04/21 |
David Clanachan
BRD | Director/Board Member | 62 | 29/04/21 |
Walter Robb
BRD | Director/Board Member | 70 | 29/04/21 |
1st Jan change | Capi. | |
---|---|---|
+29.98% | 684B | |
+30.34% | 568B | |
-3.52% | 361B | |
+18.59% | 329B | |
+4.07% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+7.09% | 166B |